Chemistry:N-Desethylprotonitazene
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, intransal, vaporized |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C21H26N4O3 |
| Molar mass | 382.464 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
N-Desethylprotonitazene is a benzimidazole opioid with potent analgesic effects which has been sold as a designer drug. It was first identified in 2024 as an active metabolite of the closely related compound protonitazene,[1][2] and was found to have less potency than it while still being more potent than fentanyl.[3][4]
It was discovered in a drug sample from Chicago in June 2025.[3]
See also
References
- ↑ "In vitro characterization of protonitazene metabolites, using human liver microsomes, and first application to two urines collected from death cases". Clinica Chimica Acta; International Journal of Clinical Chemistry (Elsevier BV) 561: 119764. Jul 2024. doi:10.1016/j.cca.2024.119764. ISSN 0009-8981. PMID 38844019.
- ↑ "In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids". Archives of Toxicology (Springer Science and Business Media LLC) 98 (9): 2999–3018. June 14, 2024. doi:10.1007/s00204-024-03774-7. ISSN 0340-5761. PMID 38877156. PMC 11324687. Bibcode: 2024ArTox..98.2999D. https://link.springer.com/content/pdf/10.1007/s00204-024-03774-7.pdf. Retrieved July 19, 2025.
- ↑ 3.0 3.1 "Monographs". June 16, 2025. https://www.cfsre.org/nps-discovery/monographs/n-desethyl-protonitazene.
- ↑ "Substance Details N-desethyl protonitazene". https://www.unodc.org/LSS/Substance/Details/6FB12561-37C2-4B79-AFE9-130D76DE8CA6.
 |  |
